A Phase 3 interventional study of Acotiamide hydrochloride hydrate and Placebo in Functional Dyspepsia, sponsored by Zeria Pharmaceutical. Completed at 1 site in Japan. Open to participants aged 9 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Zeria Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing Z 338 in Dyspepsia — 1 open to participants now, 1 under way, none of them phase 3. Z 338 · Dyspepsia.
Among the 11 studies testing Z 338 in Dyspepsia, this one is the 9th largest by enrollment, is the only one that started in 2021, is one of 4 in phase 3, and was the 10th registered.
372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.
Browse Dyspepsia studies →1 of the 11 studies testing Z 338 in Dyspepsia is open now. Recruiting first, the newest first:
Aga Khan University
Ages 18–70
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 9 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2021.
This study's enrollment of 55 is below the median of 89 across 302 interventional studies indexed under Dyspepsia.
Median enrollment 282 across the 11 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 3 most frequent:
Zeria Pharmaceutical is the lead sponsor of 23 studies on the registry; none are open to participants now.
Zeria Pharmaceutical has 7 studies filed under Dyspepsia — fewer than ten, so there is no comparison to draw.
1 of the studies testing Z 338 in Dyspepsia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07449689Aga Khan UniversityComparing Acotiamide and Itopride for the Management of Indigestion | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing Z 338 in Dyspepsia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate pharmacokinetics, efficacy and safety of Z-338 of pediatric patients with functional dyspepsia (FD).
In Part 1, the pharmacokinetics and safety of single oral dose of Z-338 100 mg are evaluated.
In Part 2, the efficacy and safety of Z-338 100 mg orally 3 times daily before meals are evaluated.
Part 2 is comprised by the double-blind phase and the open-label phase. In the double-blind phase, subjects will take Z-338 or placebo for 28 days. In the open-label phase, all subjects will take Z-338 for 28 days.
Main Inclusion Criteria:
Part 1\& Part 2
Part 2 only
Main Exclusion Criteria:
Part 1\&Part 2
Part 2 only
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Acotiamide hydrochloride hydrate
Drug: Placebo
A white film-coated tablet containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase Administered orally, one tablet a time and three times a day before meals for 28 days in the open-label phase
A white film-coated tablet not containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase
Cmax of single dose Z-338 before meal
Time frame: The 1 day of single dose
AUC up to 8 hours after administration of single dose Z-338 before meal
Time frame: The 1 day of single dose
Elimination rate of three symptoms (Postprandial fullness, Upper abdominal bloating and Early satiation)
Time frame: At week 4 of treatment or treatment discontinuation
Overall responder rate by the Overall Treatment Evaluation (OTE) scale
Time frame: At week 4 of treatment or treatment discontinuation
Elimination rate of each symptom
Time frame: Weekly from the day of randomization to Week 8
Average severity score of each symptom
Time frame: Weekly from the day of randomization to Week 8
Worst severity score of each symptom
Time frame: Weekly from the day of randomization to Week 8
Weekly responder rate by the OTE scale
Time frame: Weekly from the day of randomization to Week 8
Incidence of adverse events
Time frame: 8-weeks study period
Incidence of adverse drug reactions
Time frame: 8-weeks study period
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2021 to primary completion in Mar 2026, 60 months.
Of 15 phase 3 interventional studies under Dyspepsia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 60 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Z 338